Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer

Cameron M. Armstrong, Allen C Gao

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

The therapies available for prostate cancer patients whom progress from hormone-sensitive to castration resistant prostate cancer include both systemic drugs, including docetaxel and cabazitaxel, and drugs that inhibit androgen signaling such as enzalutamide and abiraterone. Unfortunately, it is estimated that up to 30% of patients have primary resistance to these treatments and over time even those who initially respond to therapy will eventually develop resistance and their disease will continue to progress regardless of the presence of the drug. Determining the mechanisms involved in the development of resistance to these therapies has been the area of intense study and several adaptive pathways have been uncovered. Androgen receptor (AR) mutations, expression of AR-V7 (or other constitutively active androgen receptor variants), intracrine androgen production and overexpression of androgen synthesis enzymes such as Aldo-Keto Reductase Family 1, Member C3 (AKR1C3) are among the many mechanisms associated with resistance to anti-androgens. In regards to the taxanes, one of the key contributors to drug resistance is increased drug efflux through ATP Binding Cassette Subfamily B Member 1 (ABCB1). Targeting these resistance mechanisms using different strategies has led to various levels of success in overcoming resistance to current therapies. For instance, targeting AR-V7 with niclosamide or AKR1C3 with indomethacin can improve enzalutamide and abiraterone treatment. ABCB1 transport activity can be inhibited by the dietary constituent apigenin and antiandrogens such as bicalutamide which in turn improves response to docetaxel. A more thorough understanding of how drug resistance develops will lead to improved treatment strategies. This review will cover the current knowledge of resistance mechanisms to castration resistant prostate cancer therapies and methods that have been identified which may improve treatment response.

Original languageEnglish (US)
Pages (from-to)185-194
Number of pages10
JournalAsian Journal of Urology
Volume3
Issue number4
DOIs
StatePublished - Oct 1 2016

Fingerprint

Castration
Prostatic Neoplasms
Androgen Receptors
docetaxel
Androgens
Therapeutics
Drug Resistance
Pharmaceutical Preparations
Niclosamide
Adenosine Triphosphate
Apigenin
Androgen Antagonists
Taxoids
Disease Resistance
Indomethacin
Hormones
Mutation
Enzymes

Keywords

  • Abiraterone
  • Castration resistant prostate cancer
  • Docetaxel
  • Drug resistance
  • Enzalutamide
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer. / Armstrong, Cameron M.; Gao, Allen C.

In: Asian Journal of Urology, Vol. 3, No. 4, 01.10.2016, p. 185-194.

Research output: Contribution to journalReview article

@article{ca1ea3dd458a413abfef04ff6494d411,
title = "Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer",
abstract = "The therapies available for prostate cancer patients whom progress from hormone-sensitive to castration resistant prostate cancer include both systemic drugs, including docetaxel and cabazitaxel, and drugs that inhibit androgen signaling such as enzalutamide and abiraterone. Unfortunately, it is estimated that up to 30{\%} of patients have primary resistance to these treatments and over time even those who initially respond to therapy will eventually develop resistance and their disease will continue to progress regardless of the presence of the drug. Determining the mechanisms involved in the development of resistance to these therapies has been the area of intense study and several adaptive pathways have been uncovered. Androgen receptor (AR) mutations, expression of AR-V7 (or other constitutively active androgen receptor variants), intracrine androgen production and overexpression of androgen synthesis enzymes such as Aldo-Keto Reductase Family 1, Member C3 (AKR1C3) are among the many mechanisms associated with resistance to anti-androgens. In regards to the taxanes, one of the key contributors to drug resistance is increased drug efflux through ATP Binding Cassette Subfamily B Member 1 (ABCB1). Targeting these resistance mechanisms using different strategies has led to various levels of success in overcoming resistance to current therapies. For instance, targeting AR-V7 with niclosamide or AKR1C3 with indomethacin can improve enzalutamide and abiraterone treatment. ABCB1 transport activity can be inhibited by the dietary constituent apigenin and antiandrogens such as bicalutamide which in turn improves response to docetaxel. A more thorough understanding of how drug resistance develops will lead to improved treatment strategies. This review will cover the current knowledge of resistance mechanisms to castration resistant prostate cancer therapies and methods that have been identified which may improve treatment response.",
keywords = "Abiraterone, Castration resistant prostate cancer, Docetaxel, Drug resistance, Enzalutamide, Prostate cancer",
author = "Armstrong, {Cameron M.} and Gao, {Allen C}",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.ajur.2016.08.001",
language = "English (US)",
volume = "3",
pages = "185--194",
journal = "Asian Journal of Urology",
issn = "2214-3882",
publisher = "Elsevier (Singapore) Pte Ltd",
number = "4",

}

TY - JOUR

T1 - Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer

AU - Armstrong, Cameron M.

AU - Gao, Allen C

PY - 2016/10/1

Y1 - 2016/10/1

N2 - The therapies available for prostate cancer patients whom progress from hormone-sensitive to castration resistant prostate cancer include both systemic drugs, including docetaxel and cabazitaxel, and drugs that inhibit androgen signaling such as enzalutamide and abiraterone. Unfortunately, it is estimated that up to 30% of patients have primary resistance to these treatments and over time even those who initially respond to therapy will eventually develop resistance and their disease will continue to progress regardless of the presence of the drug. Determining the mechanisms involved in the development of resistance to these therapies has been the area of intense study and several adaptive pathways have been uncovered. Androgen receptor (AR) mutations, expression of AR-V7 (or other constitutively active androgen receptor variants), intracrine androgen production and overexpression of androgen synthesis enzymes such as Aldo-Keto Reductase Family 1, Member C3 (AKR1C3) are among the many mechanisms associated with resistance to anti-androgens. In regards to the taxanes, one of the key contributors to drug resistance is increased drug efflux through ATP Binding Cassette Subfamily B Member 1 (ABCB1). Targeting these resistance mechanisms using different strategies has led to various levels of success in overcoming resistance to current therapies. For instance, targeting AR-V7 with niclosamide or AKR1C3 with indomethacin can improve enzalutamide and abiraterone treatment. ABCB1 transport activity can be inhibited by the dietary constituent apigenin and antiandrogens such as bicalutamide which in turn improves response to docetaxel. A more thorough understanding of how drug resistance develops will lead to improved treatment strategies. This review will cover the current knowledge of resistance mechanisms to castration resistant prostate cancer therapies and methods that have been identified which may improve treatment response.

AB - The therapies available for prostate cancer patients whom progress from hormone-sensitive to castration resistant prostate cancer include both systemic drugs, including docetaxel and cabazitaxel, and drugs that inhibit androgen signaling such as enzalutamide and abiraterone. Unfortunately, it is estimated that up to 30% of patients have primary resistance to these treatments and over time even those who initially respond to therapy will eventually develop resistance and their disease will continue to progress regardless of the presence of the drug. Determining the mechanisms involved in the development of resistance to these therapies has been the area of intense study and several adaptive pathways have been uncovered. Androgen receptor (AR) mutations, expression of AR-V7 (or other constitutively active androgen receptor variants), intracrine androgen production and overexpression of androgen synthesis enzymes such as Aldo-Keto Reductase Family 1, Member C3 (AKR1C3) are among the many mechanisms associated with resistance to anti-androgens. In regards to the taxanes, one of the key contributors to drug resistance is increased drug efflux through ATP Binding Cassette Subfamily B Member 1 (ABCB1). Targeting these resistance mechanisms using different strategies has led to various levels of success in overcoming resistance to current therapies. For instance, targeting AR-V7 with niclosamide or AKR1C3 with indomethacin can improve enzalutamide and abiraterone treatment. ABCB1 transport activity can be inhibited by the dietary constituent apigenin and antiandrogens such as bicalutamide which in turn improves response to docetaxel. A more thorough understanding of how drug resistance develops will lead to improved treatment strategies. This review will cover the current knowledge of resistance mechanisms to castration resistant prostate cancer therapies and methods that have been identified which may improve treatment response.

KW - Abiraterone

KW - Castration resistant prostate cancer

KW - Docetaxel

KW - Drug resistance

KW - Enzalutamide

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85027849256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027849256&partnerID=8YFLogxK

U2 - 10.1016/j.ajur.2016.08.001

DO - 10.1016/j.ajur.2016.08.001

M3 - Review article

VL - 3

SP - 185

EP - 194

JO - Asian Journal of Urology

JF - Asian Journal of Urology

SN - 2214-3882

IS - 4

ER -